Cancer is a complex group of diseases. As researchers learn more about the biological and molecular features which define individual cancer types, new approaches to cancer research and treatment are continually being developed. These include precision medicine, cancer immunotherapy, genetics, diagnostics and targeted treatments.
Through laboratory experiments, clinical trials, and interdisciplinary scientific exchanges, pharmaceutical and biotechnology companies, as well as academic and medical institutions, investigate cancer biology and develop potential cancer treatments. Many top oncology companies continue to invest in advancing areas such as personalized cancer medicine, artificial intelligence, cell-based therapies, antibody-drug conjugates, and novel cancer diagnostics to support progress in cancer research and patient care.
1. Precision Medicine and Molecular Profiling
These approaches study the genes that are switched on and off in cancer and investigate potential treatment options for individual cases.
In contrast to traditional cancer classification by primary tumor site and type, the growing field of molecular profiling or genomic analysis of tumors enables a more complete understanding of cancer, including the genetic alterations and associated biomarkers that affect cancer biology and tumor treatment.
Genomic sequencing can reveal the many mutations present in cancer cells as well as other molecular changes. This information can aid in the identification of potential targeted therapies for a patient’s cancer and help determine whether a patient should be considered for participation in a clinical trial. Research on circulating tumor DNA (ctDNA) – released by cancer cells as free-floating DNA fragments into the bloodstream of cancer patients – is another area currently being investigated to enable the monitoring of tumor progression, treatment effects and cancer recurrence.
2. Advancements in Immunotherapy and Cell-Based Treatments
Immunotherapy is another major focus area of the cancer research community. These approaches use components of the human immune system, including immune checkpoint inhibitors, cancer vaccines and other therapeutic approaches. This research area includes immune checkpoint inhibitors, therapeutic cancer vaccines and other classes of therapeutics, as well as efforts to engineer or otherwise modify immune cells to allow them to recognize and target cancer cells.
One type of therapy that has received considerable attention in recent years is chimeric antigen receptor T-cell (CAR-T) therapy. These are engineered cell-based treatments where patients’ T-cells are collected and then modified in the lab to recognize cancer-related targets before being returned to the patient. Following research into cell-based therapeutics for blood cancers, there is considerable interest in investigating these approaches for solid tumors as well. However, challenges involving the tumor microenvironment, immune suppression and differences between individual tumors need to be addressed. Much of the research is focused on Natural Killer cells, Tumor Infiltrating Lymphocytes, and other immune cells to investigate novel immunotherapy approaches.
3. Artificial Intelligence in Cancer Research
A growing area of work in cancer research and medicine is the use of artificial intelligence (AI). Potential applications include cancer detection using medical imaging, cancer diagnosis from pathology samples, cancer genomics, cancer drug discovery and more.
AI is being explored in different applications involving large datasets to identify patterns that can support cancer research. This can include analyzing images of tissues from samples in pathology to assist in cancer diagnosis and identify features of tumors.
Yet another area being explored by researchers involves the use of machine learning algorithms to evaluate genes, identify potential cancer treatment targets, aid in drug development and support clinical decision-making. Findings generated by AI need to be scientifically verified and clinically checked and evaluated accordingly. These technologies aim to support researchers and healthcare professionals rather than replace them.
4. Antibody-Drug Conjugates and Targeted Therapies
Antibody-drug conjugates (ADCs) are being investigated as a way to deliver a drug to cancer cells by conjugating it to an antibody that recognizes specific cancer-related targets.
The first part of the ADC is an antibody designed to recognize a structure exposed to cancer cells. This structure is called the target of the antibody. The antibody can be taken up by cancer cells via endocytosis, and the drug is released after processing by the cells. Research is currently being conducted to understand the potential use of ADCs in different tumors by exploring different antibody targets, linker systems and drug components.
Other approaches, like bispecific antibodies or small-molecule inhibitors, are under investigation too. These can, for example, address two different targets associated with cancer cells or inhibit critical signaling proteins that support the growth of cancer cells. Further research into individual cancer therapies as well as combinations with other treatments is underway.
5. Advances in Cancer Diagnostics and Liquid Biopsy
Cancer Diagnostics in Focus
Liquid biopsy: Studies using cancer-related material found in the bodily fluids of patients, including blood, are being explored for early cancer detection, treatment selection and monitoring patients for cancer recurrence or progression. Researchers are investigating whether liquid biopsy tests can support early cancer detection, treatment selection and monitoring for cancer recurrence.
Detection of early-stage cancer as well as assessment of cancer type through multi-cancer early detection (MCED) technologies, including blood-based protein or other types of biomarkers, require further investigation to establish their clinical utility in cancer patients. Another area of interest in supporting tumor characterization and precision cancer research involves advanced imaging technologies and novel molecular diagnostics.
6. Radiopharmaceuticals and Emerging Treatment Approaches
New medicines containing radioactive material are being developed in the field of oncology. These so-called radiopharmaceuticals are coupled to molecules that specifically recognize certain targets. This form of systemic therapy uses targeting molecules to deliver radioactive material to cancer cells that express specific targets. In cancer research, the field is currently being studied for the use of different isotopes, new targeting concepts and combinations with other cancer therapies. Radiotheranostics is an approach that combines diagnostic imaging and targeted radionuclide therapy to identify and/or treat cancer that expresses a particular target. Research is ongoing for several cancer types, including prostate cancer and neuroendocrine cancers.
7. Clinical Trials and Research Collaborations
Many cancer treatments are being evaluated in clinical trials, and the main goals of these studies are to assess safety, determine appropriate doses, evaluate efficacy and identify possible toxic effects.
In the earliest stages of investigation, studies look to establish safety and determine appropriate dosages. Later-stage studies include larger numbers of patients evaluating treatment effects and potential side effects. More recently, biomarker-based trials have also become an area of research. These studies look at the effects of cancer treatments based on a tumor’s molecular profile rather than where it is in the body. For top oncology companies, collaboration with biotechnology researchers, hospitals, academic institutions and diagnostic laboratories is an important part of research and development work.
Collaboration with other researchers, hospitals, academic or other institutions and diagnostic laboratories around the world provides access to additional scientific expertise, clinical and laboratory research facilities and other resources involved in cancer research.
What Lies Ahead for Cancer Care?
Future advances in cancer research and treatment are expected to involve continued investigation into precision medicine, immunotherapy, AI, and more targeted approaches to drug development and diagnostic technologies. Top oncology companies, alongside biotechnology organizations, research institutions, hospitals, and diagnostic laboratories, continue to explore new cancer research strategies and evaluate their potential clinical applications.
New technologies must undergo appropriate scientific studies, clinical testing and regulatory review to determine their applicability in specific clinical settings. Continued research and collaboration will be crucial to better understanding cancer and developing new cancer diagnostics and therapeutics.
Disclaimer: This article is intended to provide a general overview of developments in oncology research and development. It is not intended to promote or recommend any specific treatment, product, or company. Information regarding investigational therapies reflects ongoing research and should not be interpreted as evidence of safety, efficacy, or regulatory approval. Readers are encouraged to consult healthcare professionals for the most current information.
